Search

Your search keyword '"Travis, Simon P."' showing total 7 results
Start Over Author "Travis, Simon P." Language undetermined
7 results on '"Travis, Simon P."'

1. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

Author

Ungaro, Ryan C., Yzet, Clara, peter bossuyt, Baert, Filip J., Vanasek, Tomas, D Haens, Geert R., Joustra, Vincent W., Panaccione, Remo, Novacek, Gottfried, Armuzzi, Alessandro, Golovchenko, Oleksandr, Olga, Prymak, Goldis, Adrian, Travis, Simon P., Hebuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Grimaud, Jean-Charles, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P., Gomollon, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellstrom, Per M., Halfvarson, Jonas, and Colombel, Jean Frederic

Abstract

Background We aimed to describe the long-term impact of achieving endoscopic and deep remission among participants in the effect of tight control management on CD (CALM) trial. Methods We analysed medical records from patients with follow-up data since end of CALM. Patients were stratified by outcomes in CALM at 1 year: clinical remission (Crohn’s disease activity index, CDAI Results One hundred twenty-two patients with median age 29 years (IQR 22.5–37) and median disease duration 0.2 years (IQR 0.1–0.8) were included. Median follow-up time from end of CALM was 3.02 years (range 0.05–6.26 years). Fifty per cent were randomised to the tight control arm. There were no significant differences in baseline characteristics in patients with follow-up data and those lost to follow-up with the exception of a slightly higher CDEIS score in patients lost to follow-up (14.6 vs. 12.9, p = 0.04). Thirty-four patients (27.9%) had a major adverse outcome during follow-up. Patients in clinical remission at 1 year did not have significantly lower rates of the composite endpoint (log-rank p = 0.15). Patients in endoscopic and deep remission at the end of CALM were significantly less likely to have a major adverse event over time (Figures 1 and 2). After adjusting for age, disease duration, prior surgery, prior stricture, and randomisation arm, endoscopic remission (aHR 0.44, 95% CI 0.20–0.96, p = 0.038) and deep remission (aHR 0.25, 95% CI 0.09–0.72, p = 0.01) were significantly associated with lower risk of major adverse events. Conclusions Early CD patients who achieve endoscopic or deep remission after 1 year of intensive treatment are less likely to have disease progression over a median of 3 years.

Published
2019

2. Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM

Author

Reinisch, Walter, Panaccione, Remo, peter bossuyt, Baert, Filip J., Armuzzi, Alessandro, Travis, Simon P., Danese, Silvio, Sandborn, William J., D Haens, Geert R., Berg, Sofie, Maa, Jen-Fue, Petersson, Joel H., Neimark, Ezequiel, Robinson, Anne M., and Colombel, Jean Frederic

Abstract

Management of Crohn’s disease (CD) is moving towards the therapeutic goal of mucosal healing and using biomarkers of inflammation, faecal calprotectin (FC) and C-reactive protein (CRP), to monitor patient progress. CALM demonstrated superior mucosal healing in patients whose treatment was escalated based on both symptoms and biomarkers than in patients managed by symptoms alone,1 but the optimal biomarker cut-offs to predict mucosal healing have not been established yet. In this analysis, association of endoscopic outcomes with FC and CRP at cut-offs from CALM was investigated.

Published
2018

4. Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease

Author

Serra, Eva Gonçalves, Schwerd, Tobias, Moutsianas, Loukas, Cavounidis, Athena, Fachal, Laura, Pandey, Sumeet, Kammermeier, Jochen, Croft, Nicholas M, Posovszky, Carsten, Rodrigues, Astor, Russell, Richard K, Barakat, Farah, Auth, Marcus K H, Heuschkel, Robert, Zilbauer, Matthias, Fyderek, Krzysztof, Braegger, Christian, Travis, Simon P, Satsangi, Jack, Parkes, Miles, Thapar, Nikhil, Ferry, Helen, Matte, Julie C, Gilmour, Kimberly C, Wedrychowicz, Andrzej, Sullivan, Peter, Moore, Carmel, Sambrook, Jennifer, Ouwehand, Willem, Roberts, David, Danesh, John, Baeumler, Toni A, Fulga, Tudor A, Karaminejadranjbar, Mohammad, Ahmed, Ahmed, Wilson, Rachel, Barrett, Jeffrey C, Elkadri, Abdul, Griffiths, Anne M, Snapper, Scott B, Shah, Neil, Muise, Aleixo M, Wilson, David C, Uhlig, Holm H, and Anderson, Carl A

Subjects
digestive system diseases, 3. Good health
Abstract

Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype associated with a spectrum of rare Mendelian disorders. Here, we perform whole-exome-sequencing and genome-wide genotyping in 145 patients (median age-at-diagnosis of 3.5 years), in whom no Mendelian disorders were clinically suspected. In five patients we detect a primary immunodeficiency or enteropathy, with clinical consequences (XIAP, CYBA, SH2D1A, PCSK1). We also present a case study of a VEO-IBD patient with a mosaic de novo, pathogenic allele in CYBB. The mutation is present in ~70% of phagocytes and sufficient to result in defective bacterial handling but not life-threatening infections. Finally, we show that VEO-IBD patients have, on average, higher IBD polygenic risk scores than population controls (99 patients and 18,780 controls; P

5. Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease

Author

Serra, Eva Gonçalves, Schwerd, Tobias, Moutsianas, Loukas, Cavounidis, Athena, Fachal, Laura, Pandey, Sumeet, Kammermeier, Jochen, Croft, Nicholas M, Posovszky, Carsten, Rodrigues, Astor, Russell, Richard K, Barakat, Farah, Auth, Marcus KH, Heuschkel, Robert, Zilbauer, Matthias, Fyderek, Krzysztof, Braegger, Christian, Travis, Simon P, Satsangi, Jack, Parkes, Miles, Thapar, Nikhil, Ferry, Helen, Matte, Julie C, Gilmour, Kimberly C, Wedrychowicz, Andrzej, Sullivan, Peter, Moore, Carmel, Sambrook, Jennifer, Ouwehand, Willem, Roberts, David, Danesh, John, Baeumler, Toni A, Fulga, Tudor A, Carrami, Eli M, Ahmed, Ahmed, Wilson, Rachel, Barrett, Jeffrey C, Elkadri, Abdul, Griffiths, Anne M, COLORS In IBD Group Investigators, Oxford IBD Cohort Study Investigators, INTERVAL Study, Swiss IBD Cohort Investigators, UK IBD Genetics Consortium, NIDDK IBD Genetics Consortium, Snapper, Scott B, Shah, Neil, Muise, Aleixo M, Wilson, David C, Uhlig, Holm H, and Anderson, Carl A

Subjects
Adult, Male, Multifactorial Inheritance, Primary Immunodeficiency Diseases, Genes, Recessive, Cohort Studies, Loss of Function Mutation, Risk Factors, Exome Sequencing, Humans, Genetic Predisposition to Disease, Age of Onset, Child, Mosaicism, Infant, Newborn, Genetic Variation, Infant, Inflammatory Bowel Diseases, digestive system diseases, 3. Good health, Pedigree, Case-Control Studies, Child, Preschool, Mutation, NADPH Oxidase 2, Female
Abstract

Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype associated with a spectrum of rare Mendelian disorders. Here, we perform whole-exome-sequencing and genome-wide genotyping in 145 patients (median age-at-diagnosis of 3.5 years), in whom no Mendelian disorders were clinically suspected. In five patients we detect a primary immunodeficiency or enteropathy, with clinical consequences (XIAP, CYBA, SH2D1A, PCSK1). We also present a case study of a VEO-IBD patient with a mosaic de novo, pathogenic allele in CYBB. The mutation is present in ~70% of phagocytes and sufficient to result in defective bacterial handling but not life-threatening infections. Finally, we show that VEO-IBD patients have, on average, higher IBD polygenic risk scores than population controls (99 patients and 18,780 controls; P < 4 × 10-10), and replicate this finding in an independent cohort of VEO-IBD cases and controls (117 patients and 2,603 controls; P < 5 × 10-10). This discovery indicates that a polygenic component operates in VEO-IBD pathogenesis.

6. Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease

Author

Serra, Eva Gonçalves, Schwerd, Tobias, Moutsianas, Loukas, Cavounidis, Athena, Fachal, Laura, Pandey, Sumeet, Kammermeier, Jochen, Croft, Nicholas M., Posovszky, Carsten, Rodrigues, Astor, Russell, Richard K., Barakat, Farah, Auth, Marcus K. H., Heuschkel, Robert, Zilbauer, Matthias, Fyderek, Krzysztof, Braegger, Christian, Travis, Simon P., Satsangi, Jack, Parkes, Miles, Thapar, Nikhil, Ferry, Helen, Matte, Julie C., Gilmour, Kimberly C., Wedrychowicz, Andrzej, Sullivan, Peter, Moore, Carmel, Sambrook, Jennifer, Ouwehand, Willem, Roberts, David, Danesh, John, Baeumler, Toni A., Fulga, Tudor A., Karaminejadranjbar, Mohammad, Ahmed, Ahmed, Wilson, Rachel, Barrett, Jeffrey C., Elkadri, Abdul, Griffiths, Anne M., Snapper, Scott B., Shah, Neil, Muise, Aleixo M., Wilson, David C., Uhlig, Holm H., Anderson, Carl A., Zurek, Marlen, Strisciuglio, Caterina, Elawad, Mamoun, Lo, Bernice, Arancibia-Carcamo, Carolina, Bailey, Adam, Barnes, Ellie, Bird-Lieberman, Elizabeth Louise, Brain, Oliver, Braden, Barbara, Collier, Jane, East, James, Howarth, Lucy, Keshav, Satish, Klenerman, Paul, Leedham, Simon, Palmer, Rebecca, Powrie, Fiona, Simmons, Alison, Walker, Matthew, Tolkien, Zoe, Kaptoge, Stephen, Allen, David, Mehenny, Susan, Mant, Jonathan, Di Angelantonio, Emanuele, Thompson, Simon G., Yilmaz, Bahtiyar, Juillerat, Pascal, Geuking, Markus, Wiest, Reiner, Macpherson, Andrew J., Bravo, Francisco Damian, Brügger, Lukas, Carstens, Ove, Bigler, Ulrike Graf, Heimgartner, Benjamin, Rusticeanu, Monica, Schmid (-Uebelhart), Sybille, Strebel, Bruno, Tatu, Aurora, Tutuian, Radu, Øyås, Ove, Ramon, Charlotte, Stelling, Jörg, Franc, Yannick, Fournier, Nicolas, Pittet, Valerie E. H., Burnand, Bernard, Egger, Mara, Golay, Delphine, Marot, Astrid, Musso, Leilla, Pittet, Valérie, Rossel, Jean-Benoît, Seematter, Vivianne, Sommer, Joachim, Vulliamy, Rachel, Michetti, Pierre, Maillard, Michel H., Keller, Céline, Nydegger, Andreas, Schoepfe, Alain, Archanioti, Eva, Ezri, Jessica, Fraga, Montserrat, Schoepfer, Alain, Müller, Christoph, Rogler, Gerhard, Biedermann, Luc, Blattmann, Mirjam, Burk, Sabine, Dora, Barbara, Fried, Michael, Misselwitz, Benjamin, Müllhaupt, Beat, Obialo, Nicole, Pohl, Daniel, Raschle, Nadia, Scharl, Michael, Vavricka, Stephan, Von Känel, Roland, Zeitz, Jonas, Abdelrahman, Karim, Ademi, Gentiana, Borovicka, Jan, Brand, Stephan, Frei, Remus, Haarer, Johannes, Knellwolf (-Grieger), Christina, Krieger(-Grübel), Claudia, Künzler, Patrizia, Meyenberger, Christa, Meyer, Pamela, Röhrich, Nina, Sawatzki, Mikael, Schelling, Martin, Semadeni, Gian-Marco, Sulz, Michael, Zimmermann, Dorothee, Aepli, Patrick, Criblez, Dominique H., Hess, Cyrill, Richterich, Jean-Pierre, Spalinger, Johannes, Staudenmann, Dominic, Stulz, Andreas, Wöhrle, Stefanie, Thomas, Amman, Anderegg, Claudia, Köhler, Henrik, Kusche, Rachel, Antonino, Anca-Teodora, Arrigoni, Eviano, Bengoa, José M., Cunningham, Sophie, De Saussure, Philippe, Girard, Laurent, De Jong, Diana Bakker, Bastürk, Polat, Brunner, Simon, Degen, Lukas, Hruz, Petr, Bakker, Carolina Khalid-De, Niess, Jan, Balsiger, Bruno, Haldemann, Janine, Saner, Gaby, Seibold, Frank, Bauerfeind, Peter, Becocci, Andrea, Belli, Dominique, Binek, Janek, Hengstler, Peter, Boehm, Stephan, Boldanov, Tujana, Bühr, Patrick, Koller, Rebekka, Rueger, Vanessa, Senning, Arne, Burri, Emanuel, Buyse, Sophie, Cao, Dahlia-Thao, D’Angelo, Fabrizia, Delarive, Joakim, Doerig, Christopher, Hessler, Roxane, Preissler, Claudia, Rentsch, Ronald, Risti, Branislav, Ritz, Marc Alain, Steuerwald, Michael, Vögtlin, Jürg, Sagmeister, Markus, Sauter, Bernhard, Schibli, Susanne, Sokollik, Christiane, Schlauri, Hugo, Schnegg, Jean-François, Seirafi, Mariam, Spangenberger, Holger, Stadler, Philippe, Staub, Peter, Stenz, Volker, Tempia-Caliera, Michela, Thorens, Joël, Truninger, Kaspar, Urfer, Patrick, Viani, Francesco, Vouillamoz, Dominique, Zander, Silvan, Wyli, Tina, Jostins, L., Kennedy, N. A., Ahmad, T., Lamb, C. A., Edwards, C., Hart, A., Hawkey, C., Mansfield, J. C., Mowat, C., Newman, W. G., Simmons, A., Tremelling, M., Lee, J. C., Prescott, N. J., Mathew, C. G., Lees, C. W., McGovern, D. P. B., Targan, S. R., Botwin, G., Mengesha, E., Fleshner, P., Landers, C., Li, D., Rioux, J. D., Bitton, A., Côté-Daigneault, J., Daly, M. J., Xavier, R., Morris, K., Boucher, G., Cho, J. H., Abraham, C., Merad, M., Sands, B., Peter, I., Hao, K., Itan, Y., Duerr, R. H., Konnikova, L., Schwartz, M. B., Proksell, S., Johnston, E., Miladinova, V., Chen, W., Brant, S. R., Datta, L., Silverberg, M. S., Schumm, L. P., Birch, S., Giri, M., Gettler, K., Sharma, Y., Stevens, C., Lazarev, M., and Haritunians, T.

Subjects
49/31, 45, article, 45/22, 631/208/1516, 692/699/249/1570, 45/23, 631/250/249/2510/257, 631/208/248, 13, digestive system diseases, 3. Good health, 49
Abstract

Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype associated with a spectrum of rare Mendelian disorders. Here, we perform whole-exome-sequencing and genome-wide genotyping in 145 patients (median age-at-diagnosis of 3.5 years), in whom no Mendelian disorders were clinically suspected. In five patients we detect a primary immunodeficiency or enteropathy, with clinical consequences (XIAP, CYBA, SH2D1A, PCSK1). We also present a case study of a VEO-IBD patient with a mosaic de novo, pathogenic allele in CYBB. The mutation is present in ~70% of phagocytes and sufficient to result in defective bacterial handling but not life-threatening infections. Finally, we show that VEO-IBD patients have, on average, higher IBD polygenic risk scores than population controls (99 patients and 18,780 controls; P < 4 × 10−10), and replicate this finding in an independent cohort of VEO-IBD cases and controls (117 patients and 2,603 controls; P < 5 × 10−10). This discovery indicates that a polygenic component operates in VEO-IBD pathogenesis.

7. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

Author

Olga Prymak, Grażyna Rydzewska, Per M. Hellström, Silvio Danese, Geert R. D'Haens, David Laharie, Gottfried Novacek, Mathurin Fumery, Mélanie Serrero, Erik Hertervig, Xavier Hébuterne, Peter Bossuyt, Remo Panaccione, Mircea Diculescu, Vincent W. Joustra, Benjamin Pariente, Jean-Frederic Colombel, J Butler, Walter Reinisch, Clara Yzet, Laurent Peyrin-Biroulet, Marc Ferrante, Francesca Petralia, Thomas Vanasek, Fernando Gomollón, Oleksandr Golovchenko, J Petersson, Jonas Halfvarson, Filip Baert, John P. Wright, Simon Travis, Gerhard Rogler, Adrian Goldis, Ryan C. Ungaro, Alessandro Armuzzi, Carol Stanciu, Irina Gubonina, Satoshi Motoya, Stefan Schreiber, Ungaro, Ryan C, Yzet, Clara, Bossuyt, Peter, Baert, Filip J, Vanasek, Thoma, D'Haens, Geert R, Joustra, Vincent Wilhelmu, Panaccione, Remo, Novacek, Gottfried, Reinisch, Walter, Armuzzi, Alessandro, Golovchenko, Oleksandr, Prymak, Olga, Goldis, Adrian, Travis, Simon P, Hébuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Serrero, Melanie, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P, Gomollón, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellström, Per M, Halfvarson, Jona, Butler, James W, Petersson, Joel, Petralia, Francesca, Colombel, Jean-Frederic, Gastroenterology and Hepatology, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Time Factors, IBD, Anti-Inflammatory Agents, Lower risk, Severity of Illness Index, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Crohn Disease, Interquartile range, Internal medicine, Azathioprine, Medicine, Humans, Retrospective Studies, Crohn's disease, Hepatology, business.industry, Proportional hazards model, Tumor Necrosis Factor-alpha, Hazard ratio, Remission Induction, Gastroenterology, Adalimumab, medicine.disease, Inflammatory Bowel Diseases, Crohn's Disease Activity Index, Confidence interval, Hospitalization, 030104 developmental biology, Treatment Outcome, Disease Progression, Prednisone, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, Calprotectin, CDEIS, business, Follow-Up Studies
Abstract

BACKGROUND & AIMS: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS: We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS: Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS: In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy. ispartof: GASTROENTEROLOGY vol:159 issue:1 pages:139-147 ispartof: location:United States status: published

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results